Conference Coverage
Latest News
Videos
Advertisement
Shorts
0:44
Prioritizing Skin Health Checks for Patients of All Skin Tones
5 hours ago
by
Shontay Lundy
0:24
The Only UV Safety Advice You Need This July
a day ago
by
Christopher G. Bunick, MD, PhD
0:47
Why Patient Stratification Matters in Clinical Trials
4 days ago
by
Bradley Burnam
0:56
The Importance of Early PsA Treatment for Joint Health
5 days ago
by
Philip J. Mease, MD
0:31
Why Your Acne Treatments May Not Be Working
6 days ago
by
Kord Honda, MD
0:24
Why patients are moving away from injectable psoriasis treatments
7 days ago
by
Linda Stein Gold, MD
1:10
A Win for Patients and Providers: Roflumilast’s Expanded PsO Indication
12 days ago
by
Christopher G. Bunick, MD, PhD
1:00
Roflumilast Cream Approved for Children as Young as 2 With Plaque Psoriasis
13 days ago
by
Jennifer Soung, MD
0:28
Rethinking First-Line Treatment for Atopic Dermatitis
17 days ago
by
David Cotter, MD, PhD
2:18
What AbbVie’s Acquisition of Apogee Means for AD Treatment
17 days ago
by
Christopher G. Bunick, MD, PhD
GEP-Guided Treatment for Melanoma & SCC Management
New Insights in Management of Moderate Hidradenitis Suppurativa
Discover Dermatology Times NP/PA Connect™!
Personalizing Treatment for Difficult Atopic Dermatitis Cases
Connect With Dermatology Times® Wherever You Scroll
Podcasts
Dermatology Times Digital Edition
Learn more about the in-depth topics covered in the June 2026 print issue of Dermatology Times.
Lim considers mentoring and helping develop the next generation of dermatologists one of his most meaningful contributions to the specialty.
Andrew Krakowski, MD, encourages involving both caregivers and children in treatment decisions, giving young patients a sense of ownership that can significantly improve adherence.
New data show that nearly two-thirds of Sun Bus participants had never visited a dermatologist, highlighting persistent gaps in access to skin cancer care.
Career decisions in dermatology are too often driven by emotion rather than data, according to a new practice management column examining common pitfalls in contract evaluation and compensation negotiations.
Innovations in packaging, formulation design, and alternative preservation strategies may reduce preservative concentrations, but they are unlikely to eliminate the need for preservatives entirely.
Data from the BroADen trial suggest that targeting STAT6 through protein degradation may offer a novel oral approach to controlling type 2 inflammation in atopic dermatitis.
Because BCC and cSCC have high tumor mutational burdens driven by UV-induced DNA damage, they are particularly well suited to immune checkpoint inhibition.
In clinical practice, digital twins could predict how individual patients respond to treatments based on factors such as genetics, skin barrier function, and lifestyle patterns.
A phase 2 clinical trial found that topical ruxolitinib cream showed promising efficacy and safety in patients with mild to moderate hidradenitis suppurativa.
Continuing Medical Education
All News
Advertisement
Advertisement
Genetic MR links gut microbiome shifts to eczema, dermatitis, rosacea and more, spotlighting cytokines like IL‑10, IL‑18 and IL‑6 as therapeutic targets.
TRAPEDS-1 met its primary pharmacokinetic objective in children aged 6 to 11 years with moderate to severe atopic dermatitis, with no new safety signals over up to 172 weeks of tralokinumab treatment.
A new real-world study found CSU was linked to stress-related disorders, but not a broad increase in new-onset psychiatric disease.
Every week, we cut through the noise to bring clinicians the trial results, approvals, and emerging therapies that are actually moving the needle.
Recapping 5 practice-changing FDA decisions from the first half of 2026, including icotrokinra, expanded pediatric indications, and more!
The Cutaneous Connection: Representation, Education, and Revolutionizing Sunscreen for Skin of Color
In this episode, Black Girl Sunscreen CEO Shontay Lundy reveals why skin of color needs photoprotection, better formulas, and stronger clinician-industry collaboration.
Forte Biosciences' FB102 shows significant facial repigmentation in a phase 1b vitiligo trial, with gains continuing 12 weeks post-treatment and mild adverse effects.
Learn the 10 weekly dashboard metrics Kathleen Moe, MD, tracks to spot issues early, boost access, cash flow, and patient experience in her practice.
Lynk Pharmaceuticals has dosed the first patient in a phase 2 trial evaluating investigational topical pan-JAK inhibitor LNK01004 for vitiligo.
A JAMA Dermatology study suggests higher cumulative isotretinoin doses, not higher daily doses, may help reduce acne relapse.
Advertisement
FDA clears SkinStylus microneedling for under-eye wrinkles in all skin types, expanding uses for acne and abdominal scars amid booming aesthetics demand.
The FDA accepted Arcutis' supplemental NDA seeking to expand roflumilast cream 0.05% to infants aged 3 months to younger than 2 years with mild to moderate AD.
This review of the latest dermatological studies includes insights on granulomatous dermatoses during dupilumab therapy, SAAD-41 validation in alopecia, updated vitiligo trends, and more.
A 30-day trial finds multi-step, barrier-friendly skin care routine cuts acne lesions, oil and redness while boosting hydration in acne-prone skin.
A recent JAAD study identified a dual Th17/Type 2 immune signature in psoriasis that may help explain why biologic responses vary among patients.
Advertisement
Advertisement
Trending on Dermatology Times
1
Study Suggests Non-Ablative Fractional Laser Reverses Epigenetic Signatures of Skin Aging
2
The Gut-Skin Axis: New Evidence Links Microbiota to Skin Disease via Inflammatory Cytokines
3
Social Media Mythbusters: PDRN Serums
4
Bempikibart Shows Positive Phase 2a Results in Alopecia Areata
5